Studying the Impact of Metastatic Lymph Nodes in Specific Gastric Mesenteries on Prognosis After D2 Lymphadenectomy and Complete Mesogastric Excision in Gastric Cancer Patients

What this Trial Is About

Researchers are investigating the importance of metastatic lymph nodes located in specific gastric mesenteries for patients with gastric cancer who have undergone a specialized surgery called D2 lymphadenectomy plus complete mesogastric excision CME. The study aims to understand how the number and location of metastatic gastric mesenteries relate to patient prognosis, building on previous classifications of lymph node involvement and current staging standards for gastric cancer. Participants will have had surgery involving D2 lymphadenectomy plus complete mesogastric excision. The study focuses on examining metastatic lymph nodes in up to six gastric mesenteries rather than many lymph node groups to reduce labor while preserving important anatomical information. This approach integrates the anatomical distribution of metastatic lymph nodes with the metastatic count method for prognosis evaluation. During the study, researchers will analyze clinical specimens from patients who received this surgery, correlating the number and location of metastatic gastric mesenteries with overall survival over an average of three years. Patient data including pathology results, cancer staging, and surgical details will be reviewed. This observational study involves no intervention beyond standard care, with follow-up to monitor outcomes and survival.

The Clinical Significance of Examining Metastatic Lymph Nodes in Individual Gastric Mesenteries in the Patients With Gastric Cancer Undergoing Gastrectomy